Department of Pathology and Cell and Molecular Therapy, Instituto de Biomedicina de Valencia (IBV)-Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.
PLoS One. 2012;7(1):e29701. doi: 10.1371/journal.pone.0029701. Epub 2012 Jan 3.
Delayed wound healing is one of the most common secondary adverse effects associated to the therapeutic use of glucocorticoid (GC) analogs, which act through the ligand-dependent transcription factor GC-receptor (GR). GR function is exerted through DNA-binding-dependent and -independent mechanisms, classically referred to as transactivation (TA) and transrepression (TR). Currently both TA and TR are thought to contribute to the therapeutical effects mediated by GR; however their relative contribution to unwanted side effects such as delayed wound healing is unknown. We evaluated skin wound healing in transgenic mice with keratinocyte-restricted expression of either wild type GR or a mutant GR that is TA-defective but efficient in TR (K5-GR and K5-GR-TR mice, respectively). Our data show that at days (d) 4 and 8 following wounding, healing in K5-GR mice was delayed relative to WT, with reduced recruitment of granulocytes and macrophages and diminished TNF-α and IL-1β expression. TGF-β1 and Kgf expression was repressed in K5-GR skin whereas TGF-β3 was up-regulated. The re-epithelialization rate was reduced in K5-GR relative to WT, as was formation of granulation tissue. In contrast, K5-GR-TR mice showed delays in healing at d4 but re-established the skin breach at d8 concomitant with decreased repression of pro-inflammatory cytokines and growth factors relative to K5-GR mice. Keratinocytes from both transgenic mice closed in vitro wounds slower relative to WT, consistent with the in vivo defects in cell migration. Overall, the delay in the early stages of wound healing in both transgenic models is similar to that elicited by systemic treatment with dexamethasone. Wound responses in the transgenic keratinocytes correlated with reduced ERK activity both in vivo and in vitro. We conclude that the TR function of GR is sufficient for negatively regulating early stages of wound closure, while TA by GR is required for delaying later stages of healing.
伤口愈合延迟是糖皮质激素(GC)类似物治疗应用相关的最常见的继发性不良反应之一,其通过配体依赖性转录因子 GC 受体(GR)发挥作用。GR 功能通过 DNA 结合依赖性和非依赖性机制发挥,经典地称为转录激活(TA)和转录抑制(TR)。目前,TA 和 TR 都被认为有助于 GR 介导的治疗效果;然而,它们对延迟伤口愈合等不良副作用的相对贡献尚不清楚。我们评估了具有角质形成细胞特异性表达野生型 GR 或 TA 缺陷但 TR 有效的突变型 GR(K5-GR 和 K5-GR-TR 小鼠)的转基因小鼠的皮肤伤口愈合。我们的数据表明,在创伤后第 4 天和第 8 天,K5-GR 小鼠的愈合延迟相对于 WT,粒细胞和巨噬细胞的募集减少,TNF-α 和 IL-1β 的表达减少。K5-GR 皮肤中的 TGF-β1 和 Kgf 表达受到抑制,而 TGF-β3 被上调。K5-GR 相对于 WT,再上皮化率降低,肉芽组织形成减少。相比之下,K5-GR-TR 小鼠在第 4 天愈合延迟,但在第 8 天恢复皮肤破裂,同时相对于 K5-GR 小鼠减少促炎细胞因子和生长因子的抑制。相对于 WT,两种转基因小鼠的角质形成细胞在体外闭合伤口的速度较慢,与体内细胞迁移缺陷一致。总体而言,两种转基因模型早期伤口愈合的延迟与全身用地塞米松治疗引起的延迟相似。转基因角质形成细胞的伤口反应与体内和体外 ERK 活性降低相关。我们得出结论,GR 的 TR 功能足以负调控伤口闭合的早期阶段,而 GR 的 TA 则需要延迟愈合的后期阶段。